Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of rolapitant in patients with mild to moderate hepatic impairment versus healthy matched controls: A phase I, open-label, parallel group, single dose study

Trial Profile

Pharmacokinetics of rolapitant in patients with mild to moderate hepatic impairment versus healthy matched controls: A phase I, open-label, parallel group, single dose study

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2018

At a glance

  • Drugs Rolapitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Jan 2018 New trial record
    • 12 Jan 2018 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top